Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease (CTAD) Congress on December 5, 2019
November 04, 2019 16:30 ET
|
Biogen Inc.
CAMBRIDGE, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced it will host live webcasts of its oral presentation and a Q&A session related to its Alzheimer’s disease...
Cerecin appoints Dr. Xiaoping Cao as Head of CMC
January 07, 2019 02:00 ET
|
Cerecin
Singapore, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Cerecin appoints Dr. Xiaoping Cao as Head of CMC Dr. Cao will lead the Chemistry, Manufacturing and Controls (CMC) of Cerecin’s pipeline of highly...
Praxis Bioresearch Awarded $1.5 Million Fast-Track SBIR Grant for Development of Novel Prodrug Stimulant with Abuse-Deterrent Properties
August 07, 2018 08:05 ET
|
Praxis Bioresearch
MENLO PARK, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Praxis Bioresearch, a biopharmaceutical company focused on the discovery and development of novel therapeutics for chronic neuropsychiatric and...
Greystone Co-Sponsoring Zimmet Healthcare’s Annual Skilled Nursing Facilities Conference
August 06, 2018 09:30 ET
|
Greystone
NEW YORK, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Underscoring its commitment to serving the skilled nursing facility (SNF) industry with financial advisory and investment management services, Greystone...
Hydrocephalus Association Says #NOMOREBS, Brain Surgery Should Not Be the Only Treatment Option for 1 Million Americans Living with Hydrocephalus
July 31, 2018 09:00 ET
|
Hydrocephalus Association
Bethesda, MD, July 31, 2018 (GLOBE NEWSWIRE) -- Imagine being 19 months old and already having had 10 brain surgeries or 21 years old and having had over 140 brain surgeries. For the over 1 million...
India Globalization Capital: The Best of Both Worlds Approach -- CFN Media
May 01, 2018 09:48 ET
|
CFN Media
SEATTLE, WA, May 01, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication...
Praxis Bioresearch Announces Peer-Reviewed Publication of Positive Data for Novel Prodrug Stimulant with Abuse-Deterrent Properties
March 28, 2018 08:05 ET
|
Praxis Bioresearch
MENLO PARK, Calif., March 28, 2018 (GLOBE NEWSWIRE) -- Praxis Bioresearch, a biopharmaceutical company focused on the discovery and development of novel therapeutics for chronic neuropsychiatric and...
Praxis Bioresearch Presents Positive Preclinical Data for Novel Prodrug Stimulant with Abuse-Deterrent Properties at ACNP Annual Meeting
December 07, 2017 07:35 ET
|
Praxis Bioresearch
MENLO PARK, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Praxis Bioresearch, a biopharmaceutical company focused on the discovery and development of novel therapeutics for chronic neuropsychiatric and...
US FDA Grants Orphan Drug Designation for Retrotope’s RT001 in the Treatment of Phospholipase 2G6 (PLA2G6)-Associated Neurodegeneration
November 02, 2017 09:00 ET
|
Retrotope
LOS ALTOS, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Retrotope announced today that the U.S. Food and Drug Administration’s (FDA’s) Office of Orphan Products Development (OOPD) granted orphan drug...
Study of Retrotope’s deuterated polyunsaturated fatty acid drugs published in The FEBS Journal
October 30, 2017 09:00 ET
|
Retrotope
LOS ALTOS, Calif. and TORONTO, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Retrotope and collaborators, led by Dr. Brian Bennett of Queen’s University, have published a paper entitled “Deuterium-reinforced...